Reversible
protein tyrosine phosphorylation, coordinately controlled by
protein tyrosine kinases and
phosphatases, is a critical
element in signal transduction pathways regulating a wide variety of biological processes, including cell growth, differentiation, and
tumorigenesis. We have previously reported that c-Src belonging to the
Src family tyrosine kinase (SFK) becomes dephosphorylated at
tyrosine 530 (Y530) and thereby activated during
progestin-induced differentiation of human endometrial stromal cells (i.e., decidualization). In this study, to elucidate the role of decidual c-Src activation, we examined whether 4-amino-5-(4-methylphenyl)-7-(t-butyl)pyrazolo[3,4-d]
pyrimidine (PP1) and 4-amino-5-(4-chlorophenyl)-7-(t-butyl)pyrazolo[3,4-d]
pyrimidine (PP2), both potent and selective SFK inhibitors, affected the ovarian
steroid-induced decidualization in vitro. Unexpectedly, PP1 paradoxically increased the
kinase activity of decidual c-Src together with dephosphorylation of Y530 in the presence of ovarian
steroids. Concomitantly, PP1 enhanced morphological and functional decidualization, as determined by induction of decidualization markers, such as
insulin-like growth factor binding protein-1 and
prolactin. PP2 also advanced decidualization along with up-regulation of the active form of c-Src whose Y-530 was dephosphorylated. In contrast to PP1 and PP2,
herbimycin A, a
tyrosine kinase inhibitor with less specificity for SFKs, showed little enhancing effect on the expression of both
IGFBP-1 and active c-Src. These results suggest that SFKs, including c-Src, may play a significant role in stromal cell differentiation, providing a clue for a possible therapeutic strategy to modulate endometrial function by targeting signaling pathway(s) involving SFKs.